Stockscreener 앱 받기
5.82
4.68%
0.26
시간 외 거래:
5.90
0.08
+1.37%
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - Business Wire
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers - Business Wire
Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM - MarketBeat
Verastem (NASDAQ:VSTM) Stock Rating Upgraded by BTIG Research - MarketBeat
Discipline and Rules-Based Execution in VSTM Response - Stock Traders Daily
Why did Verastem stock jump after-hours despite an earnings miss? - MSN
Verastem (VSTM) Q4 2025 Earnings Call Transcript - AOL.com
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem stock initiated at Buy by BTIG with $19 price target - Investing.com Canada
Verastem stock initiated at Buy by BTIG with $19 price target By Investing.com - Investing.com India
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High? - Yahoo Finance
Verastem (VSTM) reports Q4 loss, beats revenue estimates - MSN
Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM - MarketBeat
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com Nigeria
Verastem Earnings Call: Early Momentum, Long Runway Risks - TipRanks
Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), Verastem (VSTM) and Align Tech (ALGN) - The Globe and Mail
Jefferies Maintains Buy on Verastem, Inc. (VSTM) March 2026 - Meyka
Verastem (VSTM) Q4 Revenue Debut Highlights Ongoing Losses And Tests Bullish Profitability Timeline - simplywall.st
Verastem 2025 Financial Results: Q4 and Annual Revenue & LossNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Jefferies reiterates Verastem stock rating on launch progress By Investing.com - Investing.com Canada
Verastem, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus
Verastem Q4 2025 Earnings Call Transcript - MarketBeat
Verastem Q4 Earnings Call Highlights - MarketBeat
Verastem: Fourth Quarter Financial Results Overview - Bitget
Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus
Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus
Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Verastem: Q4 Earnings Snapshot - KVUE
Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union
Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan
Earnings Summary: Verastem Q4 - Benzinga
Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan
Verastem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings Outlook For Verastem - Benzinga
VSTM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
1.20%
0.06%
자본화:
|
볼륨(24시간):